FDA Grants Seventh Approval under the National Priority Voucher Pilot Program

🤖 AI 摘要

FDA issued an approval for Bizengri (zenocutuzumab-zbco), a drug that treats NRG1 fusion-positive cholangiocarcinoma, an ultra-rare, aggressive cancer that forms in the bile ducts.

分析模型：rule-based-v3 · 07-09 06:59